I just looked at Regeneron’s pipeline, no hiv but plenty of cancer along with others. I wonder if the news that cytodyn has talked with regeneron might get others (Gilead) to take notice? I would think a pharma looking to get into hiv is more likely as a partner than a pharma already in hiv with an existing pipeline. Pharma sin hiv do not want to dump their existing investment so they will ignore, until they have to face the reality that there is a better drug soon on the market.